Pediatric tonsillopharyngitis--an evaluation of cefprozil in Indian patients.
OBJECTIVE
The emergence of penicillin resistant strains and the presence of co-pathogens have made the treatment of bacterial infections in children a challenge. Streptococcal tonsillopharyngitis, which is a common infection has been well treated with cefprozil, a novel third generation cephalosporin. The aim of the present study was to evaluate cefprozil in pediatric tonsillopharyngitis. An assessment of the clinical cure and bacteriological eradication rates and an overall tolerability was made.


METHODS
It was a prospective, open, non-comparative multicentric study. 316 children (mean age 6.61 years) with tonsillopharyngitis were included. Patients were given cefprozil susp 15 mg/kg/day in two divided doses a day for 10 days.


RESULTS
A clinical cure of 96.6% and bacteriological eradication of 94.29% was achieved with cefprozil. Overall tolerability of cefprozil was assessed by physicians and 46% rated tolerability of cefprozil as excellent, 38% as very good, 10% as good, 6% as fair and none as poor.


CONCLUSIONS
Cefprozil has been found to be an excellent drug of superior microbiological and clinical activity in the treatment of pediatric patients with tonsillopharyngitis. The drug also has an expanded spectrum.
Batra Hospital & Medical Research Center, New Delhi, India.
Nomeeta
N
Gupta
Abhijit
A
Mukherjee
A K
AK
Moharana
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D010612:Pharyngitis / Q000188:drug therapy* / Q000401:mortality; D011446:Prospective Studies; D012449:Safety; D014069:Tonsillitis / Q000188:drug therapy* / Q000382:microbiology; D000097670:Cefprozil
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097670:Cefprozil